PALVELLA THERAPEUTICS INC

PVLANASDAQ

🏆 #1805 by market capEarnings Nov 10US Equity

$154.90▲ $0.60 (+0.39%)

Live

1h▼ 1.0%

24h▲ 0.4%

7d▲ 0.3%

14d▲ 8.5%

30d▲ 6.0%

1y▲ 259.4%

🏦Market Cap

$2.22B

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $154.14 – $156.56
52-Week Range: $40.92 – $161.38
Volume: $3.90B
Avg Volume: $3.84B
Shares Outstanding: 14.3M
Next Earnings: Sep 29, 2026

Fundamentals Snapshot

Annual Revenue: $463M
Last Q Revenue: $113M
P/E Ratio: -31.9
P/S Ratio: 0.0x
EPS (TTM): $-4.30
Dividend Yield: 0.00%

Why Investors Own PVLA

✓High-growth profile — revenue up +20.0% YoY with expanding US Equity exposure.
✓Healthy economics — 69% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$463M▲ +23.5% YoY

Gross Margin (TTM)

68.7%▲ +2.3% YoY

Operating Income (TTM)

$38M▲ +23.5% YoY

Free Cash Flow (TTM)

$72M▲ +23.5% YoY

About PALVELLA THERAPEUTICS INC

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

🦦